Literature DB >> 15831609

Bridging the treatment gap: the secondary care perspective.

M Dancy1.   

Abstract

Protocols and integrated care pathways can be valuable in the hospital care of patients with heart failure or left ventricular systolic dysfunction after acute myocardial infarction. A designated member of staff, often a specialist nurse, must be responsible for identifying patients suitable for management by the protocol and for ensuring that the protocol is adhered to. A new training scheme for "limited echocardiography" might enable specialist nurses to investigate left ventricular function within the first 24 hours of admission. Patients should be discharged from hospital as soon as they are out of danger. At present, they are often kept in hospital for process reasons. A "continuing care" clinic run by a specialist nurse, where patients can be seen daily after discharge until they are stabilised, is one way of bridging the gap between secondary and primary care. Communication between secondary and primary care needs to improve and same day discharge summaries are essential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831609      PMCID: PMC1876345          DOI: 10.1136/hrt.2005.062083

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  2 in total

Review 1.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

Review 2.  Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF.

Authors:  Gregg C Fonarow
Journal:  Rev Cardiovasc Med       Date:  2004       Impact factor: 2.930

  2 in total
  1 in total

1.  Development of a patient-centred care pathway across healthcare providers: a qualitative study.

Authors:  Tove Røsstad; Helge Garåsen; Aslak Steinsbekk; Olav Sletvold; Anders Grimsmo
Journal:  BMC Health Serv Res       Date:  2013-04-01       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.